DLL3 (delta-like protein 3) expression correlates with stromal desmoplasia and lymph node metastases in medullary thyroid carcinomas
| Autor: | Tim Brandenburg, Henning Dralle, Dagmar Führer-Sakel, Moritz Goetz, Hans-Ulrich Schildhaus, Marc Ingenwerth, Frank Weber, Kurt Werner Schmid, Sarah Theurer |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pathology
medicine.medical_specialty Stromal cell endocrine system diseases Endocrinology Diabetes and Metabolism Medizin DLL3 Neuroendocrine tumors lcsh:Diseases of the endocrine glands. Clinical endocrinology Thyroid carcinoma 03 medical and health sciences 0302 clinical medicine Endocrinology medullary thyroid carcinoma Internal Medicine medicine thyroid cancer Lymph node Thyroid cancer lcsh:RC648-665 business.industry Research Thyroid medicine.disease Desmoplasia medicine.anatomical_structure stromal desmoplasia 030220 oncology & carcinogenesis Immunohistochemistry 030211 gastroenterology & hepatology notch pathway medicine.symptom business |
| Zdroj: | Endocrine Connections Endocrine Connections, Vol 10, Iss 3, Pp 283-289 (2021) |
| ISSN: | 2049-3614 |
| Popis: | Medullary thyroid carcinomas (MTC) are rare and aggressive neuroendocrine tumors of the thyroid. About 70% of MTC are sporadic; approximately 50% of those harbor somatic RET mutation. DLL3 is widely expressed in many neuroendocrine tumors and has been evaluated as a potential therapeutic target. Since stromal desmoplasia in sporadic MTC has been identified as a reliable predictor of aggressive behavior and development of lymph node metastases, a possible correlation of DLL3 expression with the presence of stromal desmoplasia was of particular interest. 59 paraffin-embedded samples of sporadic MTC with (44 cases) and without (15 cases) stromal desmoplasia and known lymph node status were included. DLL3 expression was determined by immunohistochemistry; no expression (0%), low expression (1–49%) and high expression (≥50%) were correlated with clinicopathological data. The proportion of DLL3 positivity was significantly correlated with both stromal desmoplasia (P < 0.0001) and lymph node metastases (P < 0.0001). MTC without stromal desmoplasia consistently lack DLL3 expression. This is the first study to focus on MTC regarding DLL3 expression and the relationship to various factors. Our results demonstrate that expression of DLL3 in MTC represents a reliable surrogate marker for stromal desmoplasia and lymph node metastases and might be an indicator for aggressive clinical behavior. DLL3 expression in ≥50% of tumor cells virtually excludes MTC without stromal desmoplasia. DLL3 was discussed as a potential therapeutic target in malignant tumors of other locations with positive immunohistochemical reaction and might therefore be a new therapeutic option in MTC, as well. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|